Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma

2024; Elsevier BV; Volume: 207; Linguagem: Inglês

10.1016/j.ejca.2024.114172

1879-0852

Rik J. Verheijden, F.H. Burgers, Josephine C Janssen, Anouk E Putker, S. Veenstra, Geke A.P. Hospers, Maureen J.B. Aarts, Karel W Hehenkamp, Veerle L E Doornebosch, Marthe Verhaert, Franchette W.P.J. van den Berkmortel, Katerina Chatzidionysiou, Arturo Llobell, Milton Barros, Alexandre T J Maria, Akari Takeji, José-Salvador García Morillo, Merav Lidar, Mick J M van Eijs, Christian U. Blank, Sandrine Aspeslagh, Djura Piersma, Ellen Kapiteijn, Mariëtte Labots, Marye J. Boers‐Sonderen, Astrid A.M. van der Veldt, John B.A.G. Haanen, Anne M. May, Karijn P M Suijkerbuijk,

Melanoma and MAPK Pathways

Recent studies indicate an association between immunosuppression for immune-related adverse events (irAEs) and impaired survival in patients who received immune checkpoint inhibitors. Whether this is related to corticosteroids or second-line immunosuppressants is unknown. In the largest cohort thus far, we assessed the association of immunosuppressant type and dose with survival in melanoma patients with irAEs.